Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of cholangiocarcinoma. We therefore examined whether in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, D, Ojima, H, Kokubu, A, Ochiya, T, Kasai, S, Hirohashi, S, Shibata, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676540/
https://www.ncbi.nlm.nih.gov/pubmed/19319137
http://dx.doi.org/10.1038/sj.bjc.6604988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676540/
https://www.ncbi.nlm.nih.gov/pubmed/19319137
http://dx.doi.org/10.1038/sj.bjc.6604988

Ejemplares similares